Gossamer Bio to Present Data at European Respiratory Society Congress 2024

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, has announced its participation in the European Respiratory Society (ERS) Congress 2024. This event will be held both online and onsite in Vienna, Austria from September 7th to 11th. The company, which focuses on the development and commercialization of seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present significant data from its studies.

Two oral presentations and one poster presentation will be given, showcasing data relevant to seralutinib. These presentations will highlight the sustained effects and potential benefits of seralutinib, particularly from the Phase 2 TORREY open-label extension study.

Faheem Hasnain, Co-Founder, CEO, and Chairman of Gossamer Bio, expressed excitement over the new findings. He stated, "We are thrilled to present additional findings from our Phase 2 TORREY open-label extension study at the European Respiratory Society Conference in Vienna which highlight the sustained effect of seralutinib beyond 24 weeks of treatment." Hasnain emphasized that the continued improvement in clinical outcomes and the sustained effect on circulating biomarkers related to PAH pathogenesis indicate seralutinib's potential to significantly improve the lives of those suffering from pulmonary hypertension. He added, "These findings reinforce our commitment to advancing the development of seralutinib for the treatment of patients with PAH and PH-ILD."

The first oral presentation, titled "Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension," will be given by Dr. Vallerie V. McLaughlin. This session is part of the "Novel Aspects in Pulmonary Hypertension" series and is scheduled for September 8th from 2:15pm to 3:30pm CEST, with the presentation set for 2:25pm CEST in Lehar 3.

The second oral presentation, "Sustained effect of seralutinib on circulating biomarkers in the TORREY phase 2 open-label extension study," will be presented by Prof. Hossein-Ardeschir Ghofrani. This presentation will also take place during the "Novel Aspects in Pulmonary Hypertension" session on September 8th between 2:15pm and 3:30pm CEST, with a presentation time of 2:30pm CEST in Lehar 3.

Additionally, a poster presentation titled "Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells" will be presented by Prof. Soni S. Pullamsetti. This will occur on September 8th from 12:30pm to 2:20pm CEST in the Poster Area, PS-30.

Gossamer Bio is dedicated to developing and commercializing seralutinib to treat pulmonary hypertension. The company aims to become a leader in this field and improve the lives of patients living with these conditions. The data to be presented at the ERS Congress 2024 underscores the company's commitment to advancing its clinical programs and offers hope for better treatment options for those affected by PAH and PH-ILD.